1. Introduction {#sec0001}
===============

Network sensitive imaging techniques, especially resting state functional connectivity MRI (rs-fcMRI), have become increasingly important tools to investigate the pathophysiology of neurodegenerative and psychiatric diseases. In the case of Alzheimer\'s disease (AD), initial reports of decreased default network connectivity in sporadic, late-onset AD (LOAD) have been replicated across a wide spectrum of impairment ([@bib0004], [@bib0003]; [@bib0014]; [@bib0015]; [@bib0017]; [@bib0031]; [@bib0035]; [@bib0036]; [@bib0038]). In addition to LOAD, decreased default network connectivity has also been well-described in early onset AD (EOAD; ([@bib0020])) and genetically-driven, autosomal dominant AD (ADAD; ([@bib0007]; [@bib0008]; [@bib0039]). More recent studies that examine multiple networks in the same sample suggest that the degradation of the default network across the spectrum of AD is accompanied by decreased connectivity in a subset of other networks, particularly the salience, dorsal attention, and control networks ([@bib0007]; [@bib0039]), and that the variation in clinical presentation in AD corresponds to variations in networks targeted by the disease process ([@bib0019]; [@bib0020]; [@bib0025]). Importantly, several reports have closely linked connectivity in AD-targeted networks to memory performance ([@bib0006]; [@bib0011], [@bib0019]; [@bib0013]; [@bib0028]; [@bib0033]; [@bib0037]; [@bib0041]), suggesting that rs-fcMRI may provide an intermediate measure linking AD pathology to cognitive decline.

However, despite relatively consistent findings of altered rs-fcMRI in AD using multiple analytic methods and cohorts, the development of rs-fcMRI metrics as usable biomarkers in clinical and translational research settings has been slowed by difficulties with measurement reliability and longitudinal rs-fcMRI analysis. Owing to a variety of analytic and technical obstacles, reports of longitudinal fcMRI have been fairly few in number, with many focusing on age-related longitudinal change ([@bib0010]; [@bib0024]; [@bib0026]; [@bib0028]; [@bib0037]). With respect to AD, longitudinal reports of rs-fcMRI changes over time ([@bib0009]; [@bib0016]; [@bib0032]; [@bib0040]; [@bib0042]) have not specifically assessed how the presence and amount of β-amyloid (Aβ) pathology relate to longitudinal network degradation, an omission which is particularly problematic given that elevated Aβ is one of the defining neuropathologic features of AD. In the present report, we begin to address these issues by leveraging a sample of mildly-impaired older adults followed with longitudinal rs-fcMRI and with available PiBPET to assess fibrillar Aβ burden. This clinically relevant group has been followed closely with longitudinal cognitive measures; Mini Mental State Exam (MMSE) and Clinical Dementia Rating (CDR), as well as structural MRI, allowing us to place rs-fcMRI changes in the context of commonly used clinical measures and imaging biomarkers. This cohort (*N* = 24) has the additional advantage that rs-fcMRI was assessed on a relatively frequent basis during longitudinal follow-up, with the median participant having 5 available rs-fcMRI sessions over approximately 3 years of follow-up.

We utilize template based rotation (TBR) and the network templates derived from ([@bib0030]), in which we have previously demonstrated: cross-sectional relationships between functional connectivity in cognitive networks and cognitive performance ([@bib0033]); an association between baseline rs-fcMRI and longitudinal decline on the preclinical Alzheimer\'s disease cognitive composite (PACC), particularly in high Aβ individuals ([@bib0002]); AD specific profiles of network disruption ([@bib0007]); cross-sectional relationships to Aβ and tau pathology in cognitively normal elderly ([@bib0029]); and sensitivity to manipulation of the cholinergic system with scopolamine, including a strong relationships between change in rs-fcMRI and subsequent changes to mnemonic memory performance ([@bib0006]). In addition to the standard network descriptions from [@bib0030], which include an anti-correlated default mode and salience networks, we also include new template maps for independent default mode and salience networks.

Using this densely-sampled cohort, we test for difference in longitudinal rs-fcMRI change between low and high Aβ subjects. We then compare the fcMRI results to MMSE and hippocampal volume in order to compare the size and independence of the rs-fcMRI effects.

2. Methods {#sec0002}
==========

2.1. Participants {#sec0003}
-----------------

24 participants (Female = 6 (25%), age range = 65--83 years) underwent multiple longitudinal structural and resting-state functional MRI (rs-fcMRI) scans, as well as a Pittsburgh compound B positron emission tomography (PIB-PET) scan during the course of the study. All participants completed the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating scale (CDR). To be included in this study, participants were required to possess at least four rs-fcMRI scans (one completed four scans, twelve completed five scans, three completed six scans, and eight completed seven scans; median = 5 scans) over a period of approximately 3 years. The mean follow-up period was 2.75 years (±5 months, minimum = 1.6 years, maximum = 3.2 years) for a total of 138 observations across the 24 participants. MRI scans were obtained at baseline, 3-months, 6-months, 12-months, 18-months, 24 months, and 36 months, though resting state fMRI data was not collected at every session. For the sample being used here, we have 15 baseline observations, 20 at 3-months, 16 at 6-months, 24 at 1 year, 23 at 18-months, 19 at 24 months, and 20 at 36 months (see [Fig. 1](#fig0001){ref-type="fig"}). For subjects without an fcMRI measure at baseline, the zero time was set as the first resting state fMRI scan.Fig. 1The timing of fcMRI data collection over a three-year period is shown for each subject.Fig 1

Additionally all 24 participants were required to demonstrate clinically-significant cognitive impairment during the study period. None of the participants were clinically demented at baseline, and met ADNI criteria for MCI at the first instance of CDR 0.5. Accordingly, participants were required to have a baseline global CDR of 0.5 (*N* = 22) or have progressed to a global CDR of 0.5 (*N* = 2) by the end of the study. These 24 subjects were then stratified according to their level of Aβ burden using previously published PiB-PET thresholds (see below). Using this approach, 12 participants were categorized as low-Aβ and 12 as high-Aβ. Six of the subjects were APOE ε4 carriers, 11 were ε4 negative, and 7 did not receive APOE genotyping. Baseline demographics, including breakdowns by Aβ status can be found in [Table 1](#tbl0001){ref-type="table"}.Table 1Demographics table showing the whole sample and the sample split by amyloid status. Variables in bold font show a significant difference between low and high amyloid groups, namely low-PiB subjects have an average MMSE score 1.6 points higher, and on average have four months longer follow-up. All non-categorical variables are shown as means ± 1 standard deviation.Table 1AllLow PiB \< 1.186High Pib \> 1.186N241212Age75.6 ± 5.374.0 ± 6.177.3 ± 4**Aβ Status**12 low PiB / 12 high PiB1.041.73Sex6F / 18M3F / 9M3F / 9MEducation(Years)16.2 ± 2.616.2 ± 2.416.2 ± 2.8**MMSE**27 ± 228.0 ± 1.326.4 ± 2.1**Follow up (Years)**2.75 ± 0.432.92 ± 0.142.57 ± 0.54

2.2. Standard protocol approvals, registrations and patient consents {#sec0004}
--------------------------------------------------------------------

Study protocols were approved by the Partners Healthcare Institutional Review Board, and all participants provided written informed consent prior to the completion of any study procedures.

2.3. MR imaging {#sec0005}
---------------

MR images were collected on a 3T Trio Tim scanner (Siemens Medical Systems, Erlangen, Germany) using 12-channel phased-array head coil. Head motion was restrained with extendable foam-padded clamps. Earplugs and noise-reduction headphones were used to attenuate scanner noise.

### 2.3.1. Structural MRI {#sec0006}

Acquisition of structural images consisted of a T1-weighted MPRAGE (160 sagittal slices, with TR = 2.3 s, TE = 2.98 ms, inversion time = 900 ms, flip angle = 9°, FOV = 256 × 240, matrix = 256 × 240, voxel size = 1 × 1 × 1.2 mm). Structural images were processed using FreeSurfer v5.1.

### 2.3.2. Functional MRI {#sec0007}

Functional data were acquired using a gradient-echo-planar pulse sequence (EPI) sensitive to BOLD contrast using the following parameters: TR = 2000 ms, TE = 30 ms, flip angle = 90°, 64 × 64 matrix, FOV = 200 mm, with 3.125 3.125 5 skip 1 mm voxels. Thirty interleaved coronal oblique slices aligned perpendicular to the anterior-posterior commissural plane covered the whole brain. Functional images were acquired in one 6.5 min run of 195 time points at each visit. A cross-hair was projected on a screen at the head of the bore, visible to participants during the scan via a mirror attached to the head coil. Instructions were to lie still, remain awake, and keep eyes open.

All resting state data were processed using SPM12 (<http://www.fil.ion.ucl.ac.uk/spm/>). Each run was slice-time corrected, followed by a single realignment and coregistration across all timepoints, where each volume was realigned to the first volume of each run, then realigned to the first session. This was followed by a second pass realignment to the mean EPI image across all sessions. The mean-across-time EPI image was then directly normalized to MNI space using the SPM12 unified segmentation and normalization routine ([@bib0005]) and then applied to the data. Spatial normalization to template space was followed by spatial smoothing with a 6 mm FWHM Gaussian kernel, followed by removal of temporal frequencies below 0.08 Hz, and temporal z-scoring of each time course.

Functional connectivity measurements were made using Template Based Rotation (TBR ([@bib0030])). Briefly, TBR works by mapping variance from a given subject\'s fMRI run to a set of *a priori* template maps. Template maps are derived from a large outside sample. The process produces a least squares fit to the template maps via a weighted linear summation of functional volumes. The weights associated with each functional volume can be interpreted as a time series that best recapitulates the spatial pattern in the templates. Full details can be found in [@bib0030].

Measures were derived for the following cognitive networks: Default Mode (DMN) / Salience (SAL), Dorsal Attention (DAN), Frontoparietal Control (Left/Right FPCN), and the Motor network using the network templates from [@bib0030]. Having the DMN and SAL in a single component means that both networks are represented with a single variance component that is positively correlated with DMN regions and negatively correlated with SAL regions. This, however, leaves open the possibility of variance components that are shared across DMN regions and orthogonal to SAL regions and vice versa. To address this issue, we also included two additional components ([Fig. 2](#fig0002){ref-type="fig"}) derived using the same data and methods, except without row-based normalization. This resulted in separate components for the DMN and SAL (see [@bib0030] for details about row-based normalization and the derivation of the template maps). [Fig. 2](#fig0002){ref-type="fig"} shows the separate DMN and SAL templates as well as the combined DMN/SAL template used for the main analyses. The addition of these two additional templates allows us to more directly assess differences between DMN and SAL networks relative to a unitary DMN/SAL network axis. Detailed depictions of the other template maps can be found in ([@bib0030] and [@bib0006]). Template maps and relevant code for TBR are publicly available at mrtools.mgh.harvard.edu. TBR connectivity measures for each session and each network were calculated by using a spatial correlation to compute the similarity of the connectivity map from each fcMRI session to the template map. One time-point from one subject was dropped due to abnormally low connectivity measures, both with respect to the subject and with respect to the sample as a whole. Manual inspection of the scan revealed notable spatial artifacts.Fig. 2To assess rs-fcMRI in DMN and SAL independently, we generated an alternate template set by omitting row-based normalization. This approach yielded separate maps for the DMN and SAL. The top row shows a surface projection of the independent DMN components. The middle row shows a surface projection of the independent SAL component. The third row shows the combined DMN/SAL template from [@bib0030].Fig 2

As with spatial group independent component analysis (ICA), when using TBR there is no explicit requirement to clean data ([@bib0027]) (e.g. motion correction, data scrubbing, nuisance regression) in advance of analysis ([@bib0030]). ICA can be written in matrix algebra as IC = *X*•M where IC is the independent components (m-voxels by n-components), M is the unmixing matrix (m-volumes by n-components), and X is the empirical data (m-voxels by n-volumes). Starting with only X, M must be discovered which then provides IC. If IC is already known, then the derivation of M is a straightforward algebraic problem that can be solved as *M *= *X* ^−^ ^1^•IC, which is precisely the TBR formulation (where *X* ^−^ ^1^ is the pseudo-inverse of the matrix X). The only assumption is that a given IC, derived on an independent dataset, is a sufficiently close approximation to a true source in X, and is independent of nuisance variance sources. This provides TBR with an implicit ability to perform blind source/signal separation even when not explicitly modeling all sources. Additionally, prior work strongly suggests that nearly all approaches to cleaning fMRI data result in lower measurement reliability ([@bib0034]), a potentially critical problem in longitudinal analyses. Given the focus here on longitudinal change in fcMRI measures and the inherent source/signal separability of TBR, we minimized data cleaning as much as possible to avoid diminished measurement reliability as a source of spurious within-subject variability across time.

2.4. PET imaging {#sec0008}
----------------

Acquisition of ^11^C Pittsburgh Compound B PET data has previously been described in detail ([@bib0001]; [@bib0018]; [@bib0036]). In brief, PiB PET images were acquired with an 8.5 to 15 mCi bolus injection followed by a 60-minute dynamic acquisition in 69 vol (12 × 15 s, 57 × 60 s). PET data were reconstructed, attenuation corrected, scatter corrected, and evaluated for excessive head motion. Data from the first 8 min post injection was used to co-register the data to the T1 image for each subject using a 6 DoF rigid body registration. A summary distribution volume ratio (DVR) computed with Logan plotting was derived from a target region composed of frontal, lateral and retrosplenial tracer uptake (FLR) and a cerebellar grey reference region. The regions comprising the FLR are known to show elevated PiB binding in AD dementia patients (8). The cutoff of PiB FLR DVR\>1.186 for Aβ positivity was derived on a reference sample using Gaussian mixture modeling as previously described ([@bib0021]; [@bib0022]b).

2.5. Clinical measures {#sec0009}
----------------------

The MMSE ([@bib0012]) and CDR ([@bib0023]) were obtained annually at baseline, 12-months, 24 months, and 36 months. Due to missing observations relative the MRI acquisitions, intermediate measures for MMSE were temporally imputed to align with MRI data. Within subject temporal imputation utilized resampling with a shape preserving piecewise cubic spline interpolation.

2.6. Analyses {#sec0010}
-------------

Analyses were performed using linear mixed effects (LME) models using the *fitlme* routine in the MATLAB 2018b statistics package using default settings. Subject level random effects for both intercept (subject) and slope (time) were included in all LME models. Models were constructed to ascertain the relationship of baseline Aβ to longitudinal change in rs-fcMRI networks. The primary effect of interest was the PiB•time interaction term. We chose to use PiB-PET as a continuous measure rather than dichotomizing, and time was based on the dates of the MRI acquisitions with 0-time set as the first rs-fcMRI scan. To control for spurious and confounding effects we included between-subjects covariates for age, sex, and years of education, including interactions with time. We also included time-varying estimates of subject motion, time-varying cortical gray matter volume, and time-varying intracranial volume to correct for variability in the FreeSurfer recons, gross differences in head size, and cortical atrophy. Subject motion was computed as the average framewise displacement across the functional run. To achieve this we computed the Euclidean distance between the origin of each frame as estimated by the realignment procedure, and then computed the average distance moved between frames. Due to between subject distributions of motion tending towards positive skew, these measures were log-transformed to generate normal distributions.

Our dependent variables included multiple fcMRI networks including the default mode with anti-correlated salience network (DMN/SAL), DMN, SAL, the dorsal attention (DAN), left and right frontoparietal control networks (rFPCN and lFPCN), primary visual (VIS), and motor (MOT) networks. To help contextualize the results, and to investigate whether fcMRI signal was capturing a unique channel of information, we also performed analyses using longitudinal hippocampal volume (HV), and longitudinal MMSE. Raw data plots (as a function of age) depicting the data being modeled are shown in [Fig. 3](#fig0003){ref-type="fig"} for the DMN/SAL ([Fig. 3](#fig0003){ref-type="fig"}A), DMN ([Fig. 3](#fig0003){ref-type="fig"}B), MMSE ([Fig. 3](#fig0003){ref-type="fig"}C), and HV ([Fig. 3](#fig0003){ref-type="fig"}D).Fig. 3Depiction of raw longitudinal data by age. Each subject is depicted with a single line. Low-PiB subjects are shown in grey with triangle markers. High-PiB subjects are shown in black with circular markers. Panel A (upper-left) shows the raw longitudinal data for the DMN/SAL network component which showed a significant PiB•Time effect. Panel B shows the independent DMN component which did not show a significant PiB•Time effect. Panel C shows the longitudinal data for the MMSE, and Panel D shows the longitudinal data for Hippocampal Volume.Fig 3

3. Results {#sec0011}
==========

3.1. Effect of Aβ on longitudinal change in fcMRI network strength {#sec0012}
------------------------------------------------------------------

The only network to show a significant PiB•Time effect was the DMN/SAL network where we observed that higher PiB-PET signal is associated with a greater rate of decline in DMN/SAL network coherence (t(125) = −3.15 *p* = 0.002; [Fig. 5](#fig0005){ref-type="fig"}A), indicating that the DMN and SAL networks are becoming less coordinated and more orthogonal. Left and Right FPCN both showed trend level effects (lFPCN: t(125) = −1.89, *p *= 0.063. rFPCN: t(125) = −1.65, *p* = 0.102). Neither the DMN alone (t(125) = −1.02 *p* = 0.310; [Fig. 5](#fig0005){ref-type="fig"}B) nor SAL alone (t(125) = −1.25, *p* = 0.213) showed a significant effect on their own, suggesting that incorporating the strength of inter-network connections between the DMN and SAL improves the ability to detect change along an AD trajectory. Standardized β estimates with error bars for all dependent variables are shown in [Fig. 4](#fig0004){ref-type="fig"}.Fig. 4Standardized beta coefficients with 95% confidence intervals for the PiB•time effect. Each measure was used individually as a dependent variable in a longitudinal LME model assessing the effects of amyloid burden over time. Only DMN/SAL, HV, and MMSE showed significant effects (*p* \< 0.05), though the left and right FPCN were observed as trend level effects. All significant effects survived multiple comparison correction.Fig 4

3.2. Effect of Aβ on longitudinal change on MMSE and Hippocampal Volume {#sec0013}
-----------------------------------------------------------------------

To contextualize the size of the DMN/SAL effect, we also ran the same model using an established AD clinical measure, the MMSE, and an established imaging marker of AD neurodegeneration, hippocampal volume ([Fig. 4](#fig0004){ref-type="fig"}). The MMSE showed a significant PiB•Time effect (t(125)= −2.56, *p *= 0.012; [Fig. 5](#fig0005){ref-type="fig"}C), as did hippocampal volume (t(125) = −3.49, *p* \< 0.001; [Fig. 5](#fig0005){ref-type="fig"}D). These values correspond to a Cohen\'s D of 0.56 for DMN/SAL, 0.46 for MMSE, and 0.62 for hippocampal volume, where 0.2 is considered a small effect, 0.5 a medium effect, and 0.8 a large effect.Fig. 5Unadjusted plots of model fits for change over time across four different variables. Panel A shows the LME model fits for DMN/SAL connectivity over time showing greater decline over time in high PiB as compare to low PiB subjects. Panel B shows similar slopes between low/high PiB groups for the independent DMN component. C shows greater decline of MMSE over time in the high-PiB group. Panel D shows greater decline in hippocampal volume over time in high-PiB subjects as compared to low-PIB subjects.Fig 5

3.3. Does longitudinal variance in DMN/SAL fcMRI overlap with MMSE or HV? {#sec0014}
-------------------------------------------------------------------------

To address this question we re-ran the longitudinal LME from above with DMN/SAL fcMRI as the dependent variable and then added time-varying MMSE and HV as covariates in the model. The PiB•Time effect on longitudinal DMN/SAL fcMRI remained largely unchanged (t(123) = −2.98, *p *= 0.003, *D* = 0.53), and we did not observe significant relationships with either MMSE (t(123) = 0.42, *p *= 0.672) or HV (t(123) = −0.70, *p *= 0.483), indicating the DMN/SAL fcMRI metric captures an aspect of disease progression not represented in these commonly used measures of cognition and neurodegeneration.

3.4. Effects on DMN/SAL fcMRI with reduced covariates {#sec0015}
-----------------------------------------------------

Due to concerns with nuisance variance and confounding factors we took a conservative approach to controlling for potentially confounding sources of variance. The models utilized here included time-varying motion, time varying cortical volume, and time varying intracranial volume. Additionally, we controlled for between subject variance in age, sex, and education (including interactions with time). As such we also wanted to report results from the simplified model: DMN \~ PiB•Time + (Time\|Subject). As expected without the additional covariates the PiB•Time effect was more robust (t(134) = 4.02, *p* \< 0.001, *D* = 0.69).

4. Discussion {#sec0016}
=============

We observed that progressive degradation of the coordinated Default-Salience network axis over a three-year period distinguished high from low Aβ clinically impaired individuals during longitudinal follow-up. Further, we observed that DMN/SAL network measurements which incorporate both within and between network connectivity were superior to measures that only assessed within-network change in the DMN or SAL. No other network showed a significant relationship between Aβ burden and longitudinal change of functional connectivity. The effect of Aβ burden on longitudinal change of DMN/SAL network coherence was similar in effect size to change in hippocampal volume and MMSE, and the DMN/SAL effect was nearly fully independent of change on both the MMSE and hippocampal volume. This suggests that DMN/SAL rs-fcMRI is capturing a unique channel of information regarding AD progression that is not reflected in hippocampal volume or MMSE.

Of the prior reports on longitudinal rs-fcMRI, our results are most comparable with [@bib0042], where inter-network correlation between the DMN and SAL was disrupted, particularly in the early MCI cohort. The significant PiB•Time effect for the DMN/SAL is also consistent with prior reports using this DMN/SAL network template ([@bib0002]; [@bib0006], [@bib0007]b; [@bib0029]; [@bib0030]; [@bib0033]). However, with the exception of [@bib0029] (where relationships with markers of AD molecular pathology were limited to the DMN and SAL), these other reports all found significant effects with other networks in addition to the DMN/SAL, especially the Left/Right FPCN. Perhaps owing to sample size, significant findings in the present report were only observed with respect to the DMN/SAL axis, with FPCN changes at a trend-level. It remains to be seen whether the DMN/SAL effect is particular to the AD pathological cascade or if it is simply a consequence of more stable longitudinal measures or modestly increased power relative to other network measures.

Though more work is needed to further develop maximally sensitive connectivity metrics, these results are promising for fcMRI as a longitudinal marker. This is especially intriguing given that many current and upcoming clinical trials are collecting resting state fMRI data for use as an exploratory secondary outcome measure, providing fertile ground for further development of fcMRI as an AD biomarker.

The results presented are best understood in the context of several important limitations. First, these results are from an early symptomatic cohort; it remains to be seen whether these results will translate to earlier preclinical stages of Alzheimer\'s disease. Second the sample size is relatively small, consisting of 24 subjects. Accordingly, the observed effect sizes should be interpreted with caution and replication in other samples will be important to confirm these results. It should also be noted the small sample size is compensated by an average of 5 observations over approximately three years. This dense sampling makes this a unique cohort relative to most currently published reports on longitudinal functional connectivity. Third, prior work strongly suggests that tau pathologic burden may be more tightly correlated with cognitive impairment as compared to Aβ burden. The lack of tau-PET imaging in the sample studied here leaves open several questions regarding the link between tau pathology and change in the DMN/SAL fcMRI that will need to be addressed in future studies.

We find these results encouraging for the use of fcMRI as a longitudinal measure of Aβ related pathological change. While rs-fcMRI is not without flaws, it remains a powerful technique for observing and measuring brain function *in-vivo*, provides a good balance of spatial and temporal resolution, uses no ionizing radiation, and is relatively low cost. This is especially true in the context of clinical trials where MRI is needed for safety monitoring, and structural MRI is used for processing of other modalities such as PET imaging. The addition of rs-fcMRI adds very little additional subject burden and is being acquired in many current and upcoming clinical trials. Although rs-fcMRI has shown promise as a functional brain measure, it has yet to fulfill its potential as a clinically useful measure for AD and other neurodegenerative diseases. This is largely due to relatively poor measurement reliability which is a product of both the high degree of dynamicity inherent to fMRI, coupled with multiple sources of nuisance variance and measurement noise. Our findings support the further development of rs-fcMRI as an AD biomarker and, more broadly, suggests that rs-fcMRI may be usable as an exploratory outcome measure in neuropsychiatric disease clinical and translational research.
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